Inclusion and Exclusion Criteria for a Multi-Center Acute Rhinosinusitis Treatment Trial

A 2026 protocol dataset from a large, multi-center, pragmatic randomized controlled trial evaluating antibiotic and non-antibiotic treatments for acute rhinosinusitis (ARS). The trial, authored by Daniel Merenstein, aims to enroll 3,720 adult participants across six U.S. regions, with approximately 60% expected to enter a randomized phase comparing four treatment strategies.

Use Cases

• Analyzing patient eligibility criteria for a large clinical trial based on the described inclusion/exclusion parameters.
• Studying the design methodology of a pragmatic trial in primary care settings as detailed in the protocol.
• Investigating treatment group allocation (e.g., antibiotics alone, placebo-antibiotics plus INCS) for comparative effectiveness research.
• Examining sample size planning and randomization strategies for a study targeting 3,720 participants.

Strengths

• Protocol describes a large-scale trial targeting 3,720 participants, providing a substantial planned sample.
• Clear methodological details including a four-group randomized design and primary outcome measures.
• Explicitly states the trial's significance for generating high-quality evidence on antibiotic stewardship.

Limitations

• Row count is unknown, which may limit suitability assessment for specific analytical tasks.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (5.5 KB), suggesting it contains only summary or criteria data, not individual patient records.

Provenance

Source

Daniel Merenstein via figshare.

Collection Method

Protocol for a randomized controlled trial.

Time Range

Protocol dated 2026; trial timeframe is not specified.

Freshness

Last updated 2026-05 17:29:09; freshness should be verified.

Geography

Six regions across the United States.